In vivo最新文献

{"title":"Ovarian Cancer and the Risk of Cataract Episodes: A Nationwide Cohort Study.","authors":"Chia-Yi Lee, Shun-Fa Yang, Elsa Lin-Chin Mai, Yu-Ling Chang, Jing-Yang Huang, Chao-Kai Chang","doi":"10.21873/invivo.14026","DOIUrl":"10.21873/invivo.14026","url":null,"abstract":"<p><strong>Background/aim: </strong>The aim of this study was to explore the potential association between ovarian cancer and cataracts using the Longitudinal Health Insurance Research Database (LHIRD) of Taiwan.</p><p><strong>Patients and methods: </strong>A retrospective cohort study was conducted, and patients with ovarian cancer were age-matched with non-ovarian cancer patients in a 1:4 ratio. A total of 4,980 and 19,920 participants were classified into the ovarian cancer and non-ovarian cancer groups, respectively. The primary outcome was the presence of cataracts and cataract surgery. Cox proportional hazard regression was used to calculate the adjusted hazard ratio (aHR) and the 95% confidence intervals (CIs) of the primary outcomes between the groups.</p><p><strong>Results: </strong>A total of 484 and cataract events were recorded in the ovarian cancer group, while 2,383 cataract events were recorded in the non-ovarian cancer group. The ovarian cancer group had a non-significantly higher incidence of cataracts compared to the non-ovarian cancer group (aHR=1.07, 95%CI=0.97-1.19, <i>p</i>=0.074), and the incidences of individuals with advanced cataracts receiving surgery were statistically equal between the ovarian cancer group and the non-ovarian cancer group (aHR=0.93, 95%CI=0.79-1.10, <i>p</i>=0.397). In subgroup analyses, differences in cataract incidences were not significant between ovarian cancer and non-ovarian cancer subgroups with different ages or durations of ovarian cancer (all <i>p</i>>0.05).</p><p><strong>Conclusion: </strong>Ovarian cancer is associated with a marginally higher incidence of cataracts and cataract surgery.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2302-2310"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetic Simulation of Optimal Lopinavir and Ritonavir Dose Combination for COVID-19: Boosting Lopinavir With Ritonavir.","authors":"Yuta Nakamaru, Ken-Ichi Sako, Naohito Ide, Yoshikazu Matsuda, Fumiyoshi Yamashita, Tomoji Maeda","doi":"10.21873/invivo.14005","DOIUrl":"10.21873/invivo.14005","url":null,"abstract":"<p><strong>Background/aim: </strong>Lopinavir (LPV) combined with ritonavir (LPV/r) was initially developed to treat human immunodeficiency virus (HIV) infection and was subsequently repurposed to treat coronavirus disease 2019 (COVID-19) during the COVID-19 pandemic. As the efficacy of LPV/r in COVID-19 treatment has not been confirmed in clinical trials, LPV/r is not included in the Japanese COVID-19 treatment guidelines. Furthermore, previous clinical studies have not demonstrated the benefit of LPV/r against COVID-19 when used at the same dose as that used to treat HIV infection. Therefore, the aim of this study was to determine the optimal LPV/r dose combination for COVID-19 treatment.</p><p><strong>Patients and methods: </strong>Based on data from healthy volunteers and patients with HIV infection, maximum-effect models were used to estimate the relationship between LPV clearance and ritonavir plasma concentration. Pharmacokinetic simulations were performed using a range of assumptions based on previously reported modeling equations.</p><p><strong>Results: </strong>The standard LPV/r dose combination of 400 mg/100 mg twice daily did not yield optimal blood concentrations. Based on the pharmacokinetic booster effect of ritonavir, the estimated optimal dose combination was 400 mg LPV boosted with 1,200 mg ritonavir.</p><p><strong>Conclusion: </strong>These findings provide a basis to quantify the booster effect of ritonavir on LPV in COVID-19 treatment and calculate the optimal LPV and ritonavir dose combination.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2101-2108"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Emergent Endoscopic Evaluation for Corrosive Injuries: Should We Do It or Not?","authors":"Ji Hyun Kim, Ji Min Kim, Bumhee Park, Jong Sun Park, Jong Hoon Park, Sun Gyo Lim, Sung Jae Shin, Kee Myung Lee, Gil Ho Lee, Choong-Kyun Noh","doi":"10.21873/invivo.14048","DOIUrl":"10.21873/invivo.14048","url":null,"abstract":"<p><strong>Background/aim: </strong>Although emergency endoscopic evaluation of patients presenting with corrosive ingestion may facilitate prognosis prediction, the role of early endoscopic evaluation remains unclear. Therefore, we aimed to select patients who required emergency endoscopic evaluation based on the initial admission information and to investigate the factors associated with Zargar grade ≥2b in patients with corrosive ingestion.</p><p><strong>Patients and methods: </strong>We retrospectively reviewed patients with corrosive ingestion who visited the emergency department between 2010 and 2023. We investigated short- and long-term endoscopic outcomes after corrosive ingestion. Using logistic regression analysis, we investigated the factors associated with endoscopic mucosal damage of Zargar grade ≥2b.</p><p><strong>Results: </strong>A total of 211 patients were enrolled. The most common reason for and type of corrosive ingestion were suicidal intent (n=138, 65.4%) and alkaline substrates (n=181, 85.5%), respectively. The median (interquartile range, IQR) of endoscopy time after admission was 455 min (235-890 min), and 92.9% (n=196) of patients underwent endoscopic evaluation within 48 h. At the initial endoscopic evaluation, 47.9% (n=101) of the patients had no mucosal injury. Stricture was observed in 2.4% (n=5) during the follow-up period, and three (1.4%) deaths occurred. In multivariate logistic analysis, bleeding events [odds ratio (OR)=12.2, 95% confidence interval (CI)=1.619-164.581, <i>p</i>=0.024] and leukocytosis (OR=2.9, 95%CI=1.138-7.331, <i>p</i>=0.023) were significant risk factors for Zargar grade ≥2b. However, the amount ingested was not revealed to be a risk factor for Zargar grade ≥2b.</p><p><strong>Conclusion: </strong>Mucosal injury was mild in most patients admitted to the emergency department after corrosive ingestion, regardless of the amount ingested.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2474-2484"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Correlation Between Aortic Stenosis and the Subsequent Incidence of Optic Neuropathy: A Population-based Cohort Study.","authors":"Chia-Yi Lee, Shun-Fa Yang, Elsa Lin-Chin Mai, Jing-Yang Huang, Chao-Bin Yeh, Chao-Kai Chang","doi":"10.21873/invivo.14009","DOIUrl":"10.21873/invivo.14009","url":null,"abstract":"<p><strong>Background/aim: </strong>To survey the potential correlation between aortic stenosis (AS) and subsequent optic neuropathies of glaucoma and ischemic optic neuropathy.</p><p><strong>Patients and methods: </strong>A retrospective cohort study was conducted with the use of the TriNetX database, a project by the US Collaborative Network which enrolled 68 healthcare institutions. PSM There were 426,980 and 426,980 people divided into the AS and non-AS groups after exclusion. The primary outcomes were the development of glaucoma and ischemic optic neuropathy. Cox proportional hazard regression was used to produce the adjusted hazard ratio (aHR) and 95% confidence interval (CI) of the optic neuropathies between groups.</p><p><strong>Results: </strong>There were 11,717 and 8,676 glaucoma episodes found in the AS and no-AS groups, and there were 566 and 391 ischemic optic neuropathy episodes found in the AS and no-AS groups. The AS group had a significantly higher risk of glaucoma (aHR=1.277, 95% CI=1.242-1.312, <i>p</i><0.001) and ischemic optic neuropathy (aHR=1.362, 95% CI=1.197-1.549, <i>p</i><0.001) compared to the non-AS population. The cumulative probability of glaucoma and ischemic optic neuropathy were significantly higher in the AS group than the non-AS group (both <i>p</i><0.001). In the multivariate analysis, the incidence of ischemic optic neuropathy was significantly higher in the AS group compared to that of the non-AS group with different characteristics except in those with Asian race, aged 20-44 years old, and aged 65-80 years old (all 95% CIs included 1).</p><p><strong>Conclusion: </strong>The existence of AS correlates to higher risk of developing glaucoma and ischemic optic neuropathy.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2133-2143"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time-to-Onset Analysis of Rhabdomyolysis Associated With Selective Serotonin and Serotonin-Noradrenaline Reuptake Inhibitors Using the Japanese Pharmacovigilance Database.","authors":"Katsuhiro Ohyama, Yuto Okuhara, Nonoka Abe, Kouji Okada, Yusuke Hori","doi":"10.21873/invivo.14007","DOIUrl":"10.21873/invivo.14007","url":null,"abstract":"<p><strong>Background/aim: </strong>In recent years, reports of serious adverse events associated with selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs) have increased. This study aimed to evaluate the association between SSRIs/SNRIs and rhabdomyolysis (RM) and its time-to-onset profiles using data from the Japanese Adverse Drug Event Report (JADER) database.</p><p><strong>Patients and methods: </strong>We extracted data from the JADER database between April 2004 and June 2023. The association between SSRIs/SNRIs and RM was evaluated using the reporting odds ratio adjusted by sex and age group [adjusted reporting odds ratio (aROR)]. A subanalysis was performed after excluding patients taking concomitant statins or fibrates. In addition, the RM expression profile was evaluated by calculating its onset time and Weibull distribution parameters, and outcomes were examined.</p><p><strong>Results: </strong>RM was associated with the SSRIs escitalopram [aROR=1.86 (1.07-3.23)], fluvoxamine [aROR=2.41 (1.64-3.54)], paroxetine [aROR=2.59 (2.04-3.30)], and sertraline [aROR=1.76 (1.14-2.72)] as well as the SNRI duloxetine [aROR=1.49 (1.00-2.21)]. The exclusion of patients receiving concomitant statins or fibrates did not significantly affect these results. The median time to onset of RM was 11-62 days, and the Weibull distribution parameter showed that the hazard types were early failure for paroxetine and duloxetine and random failure for others.</p><p><strong>Conclusion: </strong>RM should be monitored in patients treated with SSRIs/SNRIs, particularly in the first few months of administration, and our results may be helpful for the safety management of such patients.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2115-2122"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contribution of Interleukin-4 Promoter Genotypes to Gastric Cancer Risk in Taiwan.","authors":"Chun-Kai Fu, Hsu-Tung Lee, Ya-Chen Yang, Jaw-Chyun Chen, Mei-Due Yang, Yun-Chi Wang, Hou-Yu Shih, Chia-Wen Tsai, DA-Tian Bau, Wen-Shin Chang","doi":"10.21873/invivo.13990","DOIUrl":"10.21873/invivo.13990","url":null,"abstract":"<p><strong>Background/aim: </strong>Gastric adenocarcinoma (GACA) remains a major global health concern, particularly in Asia, due to its poor prognosis and complex etiology. The interaction between genetic factors and environmental exposures, such as smoking, alcohol consumption, and <i>Helicobacter pylori</i> (<i>HP</i>) infection, plays a crucial role in GACA risk.</p><p><strong>Materials and methods: </strong><i>Interleukin-4 (IL-4)</i> gene promoter polymorphic rs2243248 (T-1099G), rs2243250 (C-589T), and rs2070874 (C-33T) genotypes were analyzed in 161 GACA patients and 483 non-cancer control subjects from a Taiwanese population by PCR-RFLP methodology. The gene-environment interactions were evaluated by stratified analysis.</p><p><strong>Results: </strong>Genotypic analysis revealed no significant association between <i>IL-4</i> polymorphisms and GACA risk (all <i>p</i>>0.05). However, interactions between <i>IL-4</i> C-589T and C-33T genotypes with <i>HP</i> infection were observed (<i>p</i>=0.0114 and 0.0009). In addition, T-1099G and C-33T genotypes interacted with alcohol consumption (<i>p</i>=0.0346 and 0.0295). T-1099G and C-589T variant genotypes were associated with an increased risk of metastasis (<i>p</i>=0.0313 and 0.0118). Moreover, <i>IL-4</i> polymorphisms did not correlate with smoking behavior in influencing GACA susceptibility.</p><p><strong>Conclusion: </strong>While <i>IL-4</i> polymorphisms alone are not predictors of GACA risk, their interactions with environmental factors may contribute to the progression of the disease. Our study emphasizes the need for further research to explore the clinical implications of <i>IL-4</i> genetic variants in diverse populations and their role in GACA progression.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"1912-1923"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Pembrolizumab on Lymph Node Dissection in Patients Who Experienced Bladder Cancer Recurrence Following Radical Cystectomy.","authors":"Yoshihiko Tasaki, Takashi Nagai, Taku Naiki, Yusuke Noda, Ryosei Okawa, Misato Tomita, Yosuke Sugiyama, Yoshihisa Mimura, Kunihiro Odagiri, Nanami Ito, Yuji Hotta, Nobuhiko Shimizu, Toshiki Etani, Shuzo Hamamoto, Atsushi Okada, Yoko Furukawa-Hibi, Takahiro Yasui","doi":"10.21873/invivo.14015","DOIUrl":"10.21873/invivo.14015","url":null,"abstract":"<p><strong>Background/aim: </strong>Pelvic lymph node dissection is recommended to improve the prognosis in patients with bladder cancer undergoing radical cystectomy. Although several studies have reported an association between lymph node dissection and the efficacy of immune checkpoint inhibitors, evidence specific to bladder cancer remains lacking. This study aimed to investigate the effect of pembrolizumab on lymph node dissection during radical cystectomy in patients with bladder cancer.</p><p><strong>Patients and methods: </strong>A total of 61 patients treated with pembrolizumab were divided into those who experienced recurrence after radical cystectomy with lymph node dissection (resection group, n=45) and those with unresectable advanced bladder cancer (unresectable group, n=16). The median overall survival (mOS) and progression-free survival (PFS) were analyzed in both groups. Additionally, the association of the characteristics and number of dissected lymph nodes with the efficacy of pembrolizumab was examined in the resection group.</p><p><strong>Results: </strong>No significant differences were observed in mOS and mPFS between the resection group and the unresectable group (mOS, <i>p</i>=0.90; mPFS, <i>p</i>=0.11, respectively). In the resection group, the mOS and mPFS were not associated with lymph node positivity or negativity (mOS, <i>p</i>=0.52; mPFS, <i>p</i>=0.53, respectively). However, among patients in the resection group who had undergone neoadjuvant therapy, those with >14 resected lymph nodes exhibited significantly shorter mPFS compared with those with <14 resected lymph nodes (<i>p</i>=0.03).</p><p><strong>Conclusion: </strong>Lymph node resection was not associated with prognosis and efficacy of pembrolizumab in patients with bladder cancer. However, as the resection of more than 14 lymph nodes was associated with a poorer prognosis and reduced efficacy of pembrolizumab, treatment strategies should be carefully tailored based on the extent of lymph node dissection and the administration of neoadjuvant therapy.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2196-2208"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Vitamin D Receptor Genotypes on Taiwan Asthma Risk.","authors":"Shou-Cheng Wang, Hou-Yu Shih, Jie-Long He, Jaw-Chyun Chen, Yun-Chi Wang, Chia-Wen Tsai, Wen-Shin Chang, Te-Chun Hsia, DA-Tian Bau","doi":"10.21873/invivo.13985","DOIUrl":"10.21873/invivo.13985","url":null,"abstract":"<p><strong>Background/aim: </strong>Vitamin D plays a critical role in regulating immune function. In literature, several studies have indicated that variations in the vitamin D receptor gene (<i>VDR</i>) may be associated with the risk of asthma risk. However, the findings remain inconsistent. The current study aimed to assess the influence of <i>VDR</i> polymorphisms on both asthma risk and severity.</p><p><strong>Patients and methods: </strong>A cohort comprising 453 non-asthmatic healthy controls and 198 asthmatic cases was assembled, and the <i>VDR</i> rs731236, rs1544410, rs2228570, and rs7975232 genotypes were determined utilizing polymerase chain reaction-restriction fragment length polymorphism methodology.</p><p><strong>Results: </strong>Our findings indicated that people carrying the variant AG and AA genotypes of <i>VDR</i> rs2228570 demonstrated an elevated risk of asthma compared to wild-type GG carriers (odds ratio=1.55 and 2.19, 95% confidence interval=1.02-2.35 and 1.37-3.49; <i>p</i>=0.0507 and 0.0014, respectively). Furthermore, individuals carrying the variant A allele at <i>VDR</i> rs2228570 exhibited a higher risk of asthma than those carrying the wild-type G allele (odds ratio=1.51, 95% confidence interval=1.19-1.92; <i>p</i>=0.0008). Moreover, a significant association was observed between <i>VDR</i> rs2228570 A-carrying genotypes and increased the severity of asthma symptoms among asthmatic patients (<i>p</i> for trend=0.0024).</p><p><strong>Conclusion: </strong>The variant A allele at <i>VDR</i> rs2228570 was associated with higher asthma susceptibility, and may serve as a predictor for asthma symptom severity. Our findings encouraged further validation in larger and diverse populations to further elucidate the significance of <i>VDR</i> genotype in asthma development.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"1852-1863"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Uric Acid in Predicting Metastasis Following Definitive Radiotherapy in Patients With Head and Neck Cancer.","authors":"Sangmin Lee, Xue Li, Jin Ho Kim, Hong-Gyun Wu, Keun Yong Eom, Joo Ho Lee","doi":"10.21873/invivo.14047","DOIUrl":"10.21873/invivo.14047","url":null,"abstract":"<p><strong>Background/aim: </strong>This study investigated the prognostic value of serum uric acid (SUA) levels after definitive radiotherapy (RT) in head and neck cancer (HNC).</p><p><strong>Patients and methods: </strong>This retrospective study included patients with HNC undergoing definitive RT between January 2008 and February 2019. SUA levels were measured pre- and post-RT. Survival outcomes were analyzed using the Kaplan-Meier method, log-rank tests, and multivariable Cox regression. The optimal post-RT SUA cut-off (4.6 mg/dl) was determined <i>via</i> ROC analysis.</p><p><strong>Results: </strong>A total of 185 patients were analyzed, with a median follow-up of 63.3 months. The mean pre-treatment SUA level was 5.4 mg/dl, which decreased to 5.2 mg/dl post-treatment, though the difference was not statistically significant (<i>p</i>=0.326). A post-treatment SUA cut-off of 4.6 mg/dl demonstrated discriminatory ability for distant metastasis-free survival (DMFS) but was not predictive of overall survival or locoregional relapse-free survival (LRFS). Kaplan-Meier analysis showed that patients with post-treatment SUA ≥4.6 mg/dl had significantly poorer DMFS than those with lower levels [hazard ratio (HR)=1.25, 95% confidence interval (CI)=1.02-1.53; <i>p</i>=0.004]. Multivariable analysis confirmed post-treatment SUA ≥4.6 mg/dl (HR=5.01, <i>p</i>=0.010), HPV-negative oropharyngeal tumors (HR=5.68, <i>p</i>=0.025), and Stage IV disease (HR=4.10, <i>p</i>=0.020) as independent prognostic factors for DMFS.</p><p><strong>Conclusion: </strong>Post-treatment SUA levels may serve as a potential marker for predicting metastasis following RT in HNC.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2464-2473"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Desalinated Lava Seawater Promotes Wound Healing by MMP9 Through Activating ERK Pathways in HaCaT Cells.","authors":"Youn Kyung Choi, Jung-Il Kang, DA Hee Yang, Sang-Chul Han, Ki Ju Kim, Ha Jeong Boo, Jin Won Hyun, Young-Sang Koh, Hye-Jin Boo, Eun-Sook Yoo, Hee-Kyoung Kang","doi":"10.21873/invivo.13999","DOIUrl":"10.21873/invivo.13999","url":null,"abstract":"<p><strong>Background/aim: </strong>Wounds are injuries to skin that frequently occur in daily life. Delayed wound healing can affect quality of life. Therefore, new materials for treating skin wounds are continuously being developed. Lava seawater is a groundwater resource in the Jeju region of the Republic of Korea with high mineral content, making it popular in industrial applications such as cosmetics. Our study investigated the effect and mechanism of action of lava seawater, desalinated using electrodialysis, on wound healing.</p><p><strong>Materials and methods: </strong>HaCaT cells were cultured in media containing different concentrations of desalinated lava seawater, and scratch wound and Transwell migration assays were performed to assess wound-healing performance. The expression of matrix metalloproteinase-9 (MMP9) and extracellular signal-regulated kinase (ERK) was studied using western blotting.</p><p><strong>Results: </strong>We confirmed that the wound-healing effect of desalinated lava seawater was because of the migration of keratinocytes. Additionally, desalinated lava seawater increased the mRNA expression of vascular endothelial growth factor, platelet-derived growth factor, and angiopoietin-1, which are associated with angiogenesis. Desalinated lava seawater also promoted wound healing by inducing the expression of MMP9, which facilitated keratinocyte migration by loosening the contact between keratinocytes and the matrix. In addition, ERK was activated by desalinated lava seawater, and the expression of MMP9 was promoted, inducing migration of HaCaT cells and increasing wound closure.</p><p><strong>Conclusion: </strong>This study provides insights into the potential impact of desalinated lava seawater produced from lava seawater on wound healing, its underlying mechanism of action, and potential applications.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2035-2049"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}